

DAFTAR PUSTAKA

Hull, R., Mbele, M., Makhafola, T., Hicks, C., Wang, S. M., Reis, R. M., Mehrotra, R., Mkhize-Kwitshana, Z., Kibiki, G., Bates, D. O., & Dlamini, Z. (2020). Cervical cancer in low and middle-income countries. *Oncology letters*, 20(3), 2058–2074.

<https://doi.org/10.3892/ol.2020.11754>

Bosch, F. X., Burchell, A. N., Schiffman, M., Giuliano, A. R., de Sanjose, S., Bruni, L., Tortolero-Luna, G., Kjaer, S. K., & Muñoz, N. (2008). Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. *Vaccine*, 26 Suppl 10, K1–K16.

<https://doi.org/10.1016/j.vaccine.2008.05.064>

Tekalegn, Y., Aman, R., Woldeyohannes, D., Sahiledengle, B., & Degno, S. (2020). Determinants of VIA Positivity Among Women Screened for Cervical Precancerous Lesion in Public Hospitals of Oromia Region, Ethiopia: Unmatched Case-Control Study. *International Journal of Women's Health*, 12, 587–596.

<https://doi.org/10.2147/IJWH.S256821>

Dewi, P. I. S., Pratama, A. A., & Astriani, N. M. D. Y. (2023). Faktor Risiko Kejadian Kanker Serviks di RSUD Kertha Usada Buleleng. *ARTERI : Jurnal Ilmu Kesehatan*, 4(3), 194-199. <https://doi.org/10.37148/arteri.v4i3.285>

Coker, A. L., Sanders, L. C., Bond, S. M., Gerasimova, T., & Pirisi, L. (2001). Hormonal and barrier methods of contraception, oncogenic human papillomaviruses, and cervical squamous intraepithelial lesion development. *Journal of women's health & gender-based medicine*, 10(5), 441–449.

<https://doi.org/10.1089/152460901300233911>

Anastasiou, E., McCarthy, K. J., Gollub, E. L., Ralph, L., van de Wijgert, J. H. H. M., & Jones, H. E. (2022). The relationship between hormonal contraception and cervical dysplasia/cancer controlling for human papillomavirus infection: A systematic review. *Contraception*, 107, 1–9. <https://doi.org/10.1016/j.contraception.2021.10.018>

Tegegne, K. T., Teferi, G., Wudu, T. K., Abinew, Y., Tegegne, E. T., & Tessema, M. K. (2024). Knowledge, Attitude, Practice, and Associated Factors of Implant Use in Women, Ethiopia. *BioMed research international*, 2024, 9978336.

<https://doi.org/10.1155/2024/9978336>

Moray, K. V., Chaurasia, H., Sachin, O., & Joshi, B. (2021). A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of

etonogestrel contraceptive implant. *Reproductive health*, 18(1), 4.
<https://doi.org/10.1186/s12978-020-01054-y>

Bahamondes, L., Fernandes, A., Monteiro, I., & Bahamondes, M. V. (2020). Long-acting reversible contraceptive (LARCs) methods. *Best practice & research. Clinical obstetrics & gynaecology*, 66, 28–40. <https://doi.org/10.1016/j.bpobgyn.2019.12.002>

Komariah, S., & Nugroho, H. (2020). Hubungan Pengetahuan, Usia Dan Paritas Dengan Kejadian Komplikasi Kehamilan Pada Ibu Hamil Trimester Iii Di Rumah Sakit Ibu Dan Anak Aisyiyah Samarinda. *KESMAS UWIGAMA: Jurnal Kesehatan Masyarakat*, 5(2), 83–93. <https://doi.org/10.24903/kujkm.v5i2.835>

Karneli, N. K. ., Suwiyoga, K. ., & Sudibya, I. G. A. . (2013). Parental willingness to pay the cervical cancer vaccination cost of senior high school aged students in Badung District. *Public Health and Preventive Medicine Archive*, 1(1), 52–57.
<https://doi.org/10.53638/phpma.2013.v1.i1.p11>

Setyarini, E. (2009). Faktor-faktor yang berhubungan dengan kejadian kanker leher rahim di RSUD DR. Moewardi Surakarta. Available:
<http://eprints.ums.sc.id/3942/2/J410040010.pdf>

Ajah LO, Chigbu CO, Ozumba BC, Oguanuo TC, Ezeonu PO. Is there any association between hormonal contraceptives and cervical neoplasia in a poor Nigerian setting? *Oncotargets Ther*. 2015 Jul 27;8:1887-92. doi: 10.2147/OTT.S86472. PMID: 26251619; PMCID: PMC4524589.

Castle, Philip & Walker, Joan & Schiffman, Mark & Wheeler, Cosette. (2005). Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. *International journal of cancer. Journal international du cancer*. 117. 1007-12. 10.1002/ijc.21279.

Richards A, Dalrymple C. Abnormal cervicovaginal cytology, unsatisfactory colposcopy and the use of vaginal estrogen cream: an observational study of clinical outcomes for women in low estrogen states. *J Obstet Gynaecol Res*. 2015 Mar;41(3):440-4. doi: 10.1111/jog.12545. Epub 2014 Nov 5. PMID: 25369987.

Alrajjal, A., Pansare, V., Choudhury, M. S. R., Khan, M. Y. A., & Shidham, V. B. (2021). Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. *CytoJournal*, 18, 16.
https://doi.org/10.25259/Cytojournal_24_2021

Perkins, R. B., Guido, R. S., Castle, P. E., Chelmow, D., Einstein, M. H., Garcia, F., Huh, W. K., Kim, J. J., Moscicki, A. B., Nayar, R., Saraiya, M., Sawaya, G. F., Wentzensen, N., Schiffman, M., & 2019 ASCCP Risk-Based Management Consensus Guidelines Committee

(2020). 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. *Journal of lower genital tract disease*, 24(2), 102–131. <https://doi.org/10.1097/LGT.0000000000000525>

Bulten J, de Wilde PC, Boonstra H, Gemmink JH, Hanselaar AG. Proliferation in "atypical" atrophic pap smears. *Gynecol Oncol*. 2000 Nov;79(2):225-9. doi: 10.1006/gyno.2000.5943. PMID: 11063649.